Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment...
Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic-based therapies for the prevention and treatment...
Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic-based therapies for the prevention and treatment...
Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention...
Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention...
Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”) announced today statistically significant results in a validated preclinical model of acute and chronic kidney disease....
Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”) announced today that, on February 1, 2023, the Company will implement a 1-for-35 reverse split of its common stock following...
Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that, on January 13, 2023, the Company’s units, which trade with the ticker symbol “REVBU” will...
Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment...
Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment...